Garlic-Derived S-Allylmercaptocysteine Ameliorates Nonalcoholic Fatty Liver Disease in a Rat Model through Inhibition of Apoptosis and Enhancing Autophagy

Abstract EN

Our previous study demonstrated that administration of garlic-derived antioxidant S-allylmercaptocysteine (SAMC) ameliorated hepatic injury in a nonalcoholic fatty liver disease (NAFLD) rat model.

Our present study aimed to investigate the mechanism of SAMC on NAFLD-induced hepatic apoptosis and autophagy.

Adult female rats were fed with a high-fat diet for 8 weeks to develop NAFLD with or without intraperitoneal injection of 200 mg/kg SAMC for three times per week.

During NAFLD development, increased apoptotic cells and caspase-3 activation were observed in the liver.

Increased apoptosis was modulated through both intrinsic and extrinsic apoptotic pathways.

NAFLD treatment also enhanced the expression of key autophagic markers in the liver with reduced activity of LKB1/AMPK and PI3K/Akt pathways.

Increased expression of proapoptotic regulator p53 and decreased activity of antiautophagic regulator mTOR were also observed.

Administration of SAMC reduced the number of apoptotic cells through downregulation of both intrinsic and extrinsic apoptotic mechanisms.

SAMC also counteracted the effects of NAFLD on LKB1/AMPK and PI3K/Akt pathways.

Treatment with SAMC further enhanced hepatic autophagy by regulating autophagic markers and mTOR activity.

In conclusion, administration of SAMC during NAFLD development in rats protects the liver from chronic injury by reducing apoptosis and enhancing autophagy.